Biophysicist Samir Brahmachari, Director General of India's Council of Scientific and Industrial Research (CSIR) , announced the launch this month of an open source drug discovery (OSDD) initiative to accelerate development of new drugs to treat infectious diseases that plague the developing world. "When it comes to health, India is in a state of war. There's a war between health as a right and health as business," says Brahmachari.
Just as the original open source software was propelled by software developers motivated to contribute to large collaborative projects, proponents of OSDD believe that the global need for new low-cost drugs, particularly for treating neglected tropical diseases, will make this model effective. Because drug research is so complex, different OSDD initiatives are applying different strategies. For example, CSIR aims to have a web-enabled interactive open source platform that will list the current design challenges for developing drugs to treat drug-resistant tuberculosis, malaria, and HIV. Research teams from CSIR labs across India and from other government institutions as well as individuals from universities and industry can volunteer to contribute solutions to the posted drug design challenges. Contributions could include, for example, posting a new algorithm or information about a new drug target. As it will be open source, any scientist can contribute. Brahmachari says that as an added incentive, software will be written enabling problem solvers and contributors to receive microcredits; once a certain number of microcredits has been accrued, the person will receive a monetary reward. The first step in CSIR's OSDD initiative is the launch of an open source website hosting information about Mycobacterium tuberculosis, the bacterial pathogen that causes tuberculosis. This information includes gene sequences, expression, function, activity, and the response to drugs of all M. tuberculosis proteins as well as host-pathogen interactions (http:// mtbsysborg.igib.res.in). Challenges for designing new drugs to combat tuberculosis will be posted shortly.
India's federal government has committed $38 million for this initiative, and Brahmachari hopes to raise a third of the overall project cost from donations and charity. Sun Microsystems, a Californian technology company, has come on board as a long-term partner to "program manage" the IT part of the initiative, which like all modern drug discovery efforts involves significant computational infrastructure. "Sun will define the high level application and systems architecture for this initiative, and will provide help in identifying the appropriate software integrator for the IT part of the project," says Jaijit Bhattacharya, Director of public policy and corporate strategy at Sun Microsystems India. Sun will provide its open source software and will help in obtaining other software for the program, he says. drug discovery challenges, says about the launch "For all the reduction-to-practice postings of new chemical materials, we had requested that the solver submit a sample of the targeted chemical structures…The receipt of these samples later that year and postmarked from all around the world, was marked evidence that the model was working." Currently, InnoCentive lists a number of successes on its website such as new methods to synthesize fluorinated ethers and butanoic acid and the identification of new drug targets for treating Duchenne Muscular Dystrophy. Among the posted challenges is one to find a diagnostic biomarker for the neurodegenerative disease amyotrophic lateral sclerosis (ALS), posted by an ALS patient group called Prize4Life. The challenge was answered by a dermatologist who proposed looking for biomarkers in skin instead of blood and urine. The problem solver received a $15,000 prize for his proposal and is working with the ALS Center at Columbia University to test the skin of about 50 ALS patients for suitable biomarkers.
Last year, Novartis Institutes for Biomedical Research in Cambridge, MA, together with the Broad Institute of Harvard and MIT and Sweden's Lund University, collaborated to make all information about genes implicated in type 2 diabetes obtained from genome-wide association studies freely available on the web in an effort to speed up elucidation of the mechanisms underlying this complex disease (http://www.broad.mit. edu/diabetes/). "This complexity is one of the reasons why we took the open approach to this collaboration. Clearly it will require many laboratories to clarify how and when these genes and loci may exert their influence on the development and/or progression of diabetes," says Thomas E. Hughes, head of diabetes research at Novartis. "We are committed to having interactive and open collaborations with innovative partners from academia and biotech," he says. "It is not often that we have the injection of new information of this type in our field." If the right opportunity presents itself in the future "we would consider using this collaboration model again," says Hughes.
Taking The surest way to create a vibrant innovation network, he says, is to protect the IP it generates. "In each organization, there will be a debate, especially early on, between how much to disclose versus how much to protect," he says. However, as organizations gain more experience in this field and as IP issues get streamlined, confidence and sharing will increase. "I do not expect free-riding to be a significant problem because members will want to influence the direction of the network of researchers, and they will have to share in order to do so," says Munos. As for India's new OSDD initiative, CSIR's Brahamachari says, "I am not a socialist reformer and I am not anti intellectual property regime." He predicts that CSIR's new initiative will follow a hybrid IP model by using a "clickwrap" license that requires the users to agree that they will not file product patent applications in cases where they rely on open source data.
India's OSDD initiative is still in its infancy and it is impossible to know how successful it will be. InnoCentive's Bingham truly applauds "the CSIR objective of mainstreaming this mode of research and its widespread applicability to drug development" but suggests that CSIR could use the InnoCentive platform. Matthew Todd thinks CSIR could adopt the existing TSL network to jumpstart the OSDD project. For his part, Brahamachari is open to collaboration with these programs but still thinks India needs to go ahead with its own OSDD initiative. As Maharaj K. Bhan, head of the Indian Federal Department of Biotechnology, points out, "It is good for the country. I don't know if it will work, but champions don't look for outcomes."
